AT(N) Biomarker Classification for Alzheimer's Disease

Overview

The AT(N) classification system is a research framework established by the National Institute on Aging and Alzheimer's Association (NIA-AA) to categorize Alzheimer's disease biomarkers based on three core pathological processes: Amyloid (A), Tau (T), and Neurodegeneration (N). This framework provides a standardized approach for biomarker-based diagnosis and staging of AD. [@hansson2019]

Core Biomarker Categories

A: Amyloid Biomarkers

These biomarkers detect the presence of amyloid-beta (Aβ) plaque pathology in the brain. [@palmqvist2020]

Overview

The AT(N) classification system is a research framework established by the National Institute on Aging and Alzheimer's Association (NIA-AA) to categorize Alzheimer's disease biomarkers based on three core pathological processes: Amyloid (A), Tau (T), and Neurodegeneration (N). This framework provides a standardized approach for biomarker-based diagnosis and staging of AD. [@hansson2019]

Core Biomarker Categories

A: Amyloid Biomarkers

These biomarkers detect the presence of amyloid-beta (Aβ) plaque pathology in the brain. [@palmqvist2020]

| Biomarker | Fluid | Imaging | Key Features | [@zetterberg2019]
|-----------|-------|---------|--------------| [@khalil2018]
| Aβ42/40 ratio | CSF, Plasma | - | Decreased in AD; ratio more specific than Aβ42 alone | [@fleisher2020]
| Aβ42 | CSF | - | Decreased due to plaque deposition | [@kanemaru2020]
| Amyloid PET | - | PET (PiB, Florbetapir, Florbetaben) | Visualizes cortical amyloid binding | [@park2021]

Diagnostic Performance: [@li2022]

• CSF Aβ42/40 ratio: Sensitivity 85-95%, Specificity 85-90% for detecting cerebral amyloid
• Amyloid PET: Sensitivity 90-95%, Specificity 90-95% for neuritic plaques

T: Tau Biomarkers

These biomarkers detect tau pathology, including neurofibrillary tangles (NFTs) and tau positivities.

T (Tau) Subcategories

| Subcategory | Biomarker | Fluid | Imaging | Key Features |
|-------------|-----------|-------|---------|--------------|
| T-tau (total) | t-Tau | CSF | - | Non-specific neuronal damage marker |
| T-tau (phosphorylated) | p-Tau181, p-Tau217, p-Tau231 | CSF, Plasma | - | AD-specific, correlates with NFT burden |
| Tau PET | - | - | PET (Flortaucipir, MK-6240, PI-2620) | Visualizes tau neurofibrillary tangles |

Diagnostic Performance:

• CSF p-Tau181: Sensitivity 80-90%, Specificity 85-95% for AD
• Plasma p-Tau217: Sensitivity 85-95%, Specificity 85-90% for AD, emerging as optimal blood biomarker
• Tau PET: Sensitivity 85-95%, Specificity 85-90% for detecting tau pathology

N: Neurodegeneration Biomarkers

These biomarkers indicate neuronal injury, synaptic loss, and brain atrophy.

| Biomarker | Fluid | Imaging | Key Features |
|-----------|-------|---------|--------------|
| Total tau (t-Tau) | CSF | - | Non-specific, elevated in various dementias |
| Neurofilament Light (NfL) | CSF, Blood | - | Axonal injury marker, non-specific |
| Neurogranin | CSF | - | Synaptic marker, AD-specific |
| VILIP-1 | CSF | - | Neuronal injury marker |
| FDG-PET | - | PET | Hypometabolism in AD-vulnerable regions |
| MRI atrophy | - | MRI | Hippocampal, entorhinal cortical atrophy |

Diagnostic Performance:

• CSF t-Tau: Sensitivity 70-85%, Specificity 60-75% (less specific than p-Tau)
• CSF Neurogranin: Sensitivity 75-85%, Specificity 75-85% for AD
• Blood NfL: Sensitivity 70-85%, Specificity 65-80%, useful for disease progression

AT(N) Profiles in Clinical Practice

Normal Biomarker Profile

• A-/T-(N)-: Cognitively normal, no significant AD pathology

Alzheimer's Disease Continuum

| Stage | A | T | N | Clinical Status |
|-------|---|---|---|-----------------|
| Preclinical AD | + | - | - | Cognitively normal |
| Preclinical AD | + | + | - | Cognitively normal, downstream tau |
| MCI due to AD | + | + | -/+ | Mild cognitive impairment |
| Dementia due to AD | + | + | + | Dementia with AD pathology |

Biomarker Combinations and Clinical Utility

AT(N) Combinations for Differential Diagnosis

| Clinical Syndrome | A | T | N | Interpretation |
|------------------|---|---|---|----------------|
| Typical AD | + | + | + | AD dementia |
| AD with Lewy bodies | + | + | + | + α-synuclein markers |
| FTLD | - | + (4R) | + | Tau PET negative, no amyloid |
| Vascular dementia | - | - | + | Neurodegeneration without AD |

Blood-Based Biomarker Panels

Emerging blood-based biomarker panels are simplifying AT(N) profiling:

| Panel Components | Detection |
|-----------------|-----------|
| Aβ42/40 + p-Tau217 | A+T profile |
| p-Tau181/NfL | T+N profile |
| p-Tau217 + NfL + GFAP | Full AT(N) approximation |

Cost Comparison:

• CSF biomarker panel: $500-1000
• Amyloid PET: $3000-5000
• Tau PET: $3000-7000
• Blood biomarkers: $200-500

Non-Western Population Data

Asian Population Studies

Japanese Cohorts:

• J-ADNI studies show similar CSF Aβ42/40 ratio performance in Japanese populations
• Plasma p-Tau181 shows comparable diagnostic accuracy in Japanese cohorts

• Korean AD research network has validated amyloid PET criteria in Korean populations
• CSF p-Tau231 shows promise for early detection in Korean cohorts

• Chinese Biomarker Consortium demonstrates Aβ42/40 ratio utility
• Plasma NfL reference ranges established for Chinese populations

Regulatory Status

| Biomarker | FDA Status | CE Mark |
|-----------|------------|---------|
| Amyloid PET (Florbetapir) | Approved | Yes |
| CSF Aβ42, t-Tau, p-Tau181 | Research use only | Yes (some) |
| Plasma p-Tau (Elecsys) | FDA breakthrough device | Under review |
| Blood NfL | Research use only | Yes (some) |

Clinical Recommendations

Recommended Biomarker Panel by Setting

| Setting | First-line | Confirmatory |
|---------|-----------|--------------|
| Memory clinic | Blood Aβ42/40 + p-Tau | CSF biomarkers or PET |
| Primary care | Blood p-Tau217 | Referral for confirmation |
| Research | Full AT(N) panel | N/A |

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References

[DOI:10.1016/j.jalz.2018.02.013](https://doi.org/10.1002/alz.12008)
[DOI:10.1001/jamaneurol.2020.0981](https://doi.org/10.1001/jamaneurol.2019.0765)

Pathway Diagram

The following diagram shows the key molecular relationships involving AT(N) Biomarker Classification for Alzheimer's Disease discovered through SciDEX knowledge graph analysis: